Opus Genetics (IRD)

Executive Summary

Opus Genetics (NASDAQ: IRD) is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases (IRDs). Based on foundational research from the University of Pennsylvania, the company operates a subsidiary model to accelerate development. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for Leber congenital amaurosis (LCA) caused by LCA5 mutations. Preclinical programs target NR2E3 mutations (Enhanced S-Cone Syndrome) and RHO mutations (retinitis pigmentosa). The company aims to restore vision by delivering functional genes directly to retinal cells, addressing the underlying genetic causes of blindness. As a public company, Opus Genetics is well-positioned to advance its pipeline, though early-stage clinical data and regulatory milestones remain critical.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data for OPGx-LCA560% success
• Q4 2026IND filing for NR2E3 gene therapy program50% success